DHHS awards $115M contract to Hamilton Company for COVID-19 testing capacity expansion

Contract Overview

Contract Amount: $115,102,920 ($115.1M)

Contractor: Hamilton Company

Awarding Agency: Department of Health and Human Services

Start Date: 2022-02-17

End Date: 2024-04-30

Contract Duration: 803 days

Daily Burn Rate: $143.3K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 64

Pricing Type: FIRM FIXED PRICE

Sector: R&D

Official Description: HAMILTON COMPANY FOR MFG CAPACITY EXPANSION OF COVID-19 DHHS TESTING AND DIAGNOSTICS. THIS ACTION WAS IN SUPPORT OF DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS)

Place of Performance

Location: RENO, WASHOE County, NEVADA, 89502

State: Nevada Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $115.1 million to HAMILTON COMPANY for work described as: HAMILTON COMPANY FOR MFG CAPACITY EXPANSION OF COVID-19 DHHS TESTING AND DIAGNOSTICS. THIS ACTION WAS IN SUPPORT OF DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS) Key points: 1. Contract supports critical expansion of COVID-19 testing and diagnostics manufacturing capacity. 2. Value-for-money assessment is pending further data on performance and market benchmarks. 3. Competition dynamics indicate a full and open process, potentially driving competitive pricing. 4. Risk indicators are moderate, with contract duration and firm fixed-price structure providing some stability. 5. Performance context will be key to evaluating the effectiveness of capacity expansion. 6. Sector positioning is within R&D for physical, engineering, and life sciences, supporting public health initiatives.

Value Assessment

Rating: fair

The contract value of $115.1 million for manufacturing capacity expansion is substantial. Benchmarking this against similar investments in diagnostic manufacturing is difficult without more specific details on the scope of expansion and the technologies involved. The firm fixed-price nature suggests a defined scope, but the ultimate value will depend on the successful ramp-up of production and the cost-effectiveness of the expanded capacity compared to market alternatives or previous investments.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, suggesting that multiple vendors had the opportunity to bid. The number of bidders (64) is robust and indicates a healthy level of interest and potential competition. This broad competition is generally favorable for price discovery and ensuring the government receives competitive offers.

Taxpayer Impact: A full and open competition process increases the likelihood that taxpayer funds are used efficiently by fostering a competitive environment that can drive down costs.

Public Impact

The primary beneficiaries are the Department of Health and Human Services (DHHS) and the public, through increased availability of COVID-19 testing and diagnostics. Services delivered include the expansion of manufacturing capacity for critical testing supplies. Geographic impact is primarily focused on the location of Hamilton Company's manufacturing facilities in Nevada. Workforce implications may include job creation or expansion at the contractor's facilities.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for cost overruns if manufacturing ramp-up is more complex than anticipated.
Dependence on a single contractor for critical capacity expansion could pose supply chain risks.
Ensuring timely delivery and quality of expanded manufacturing output requires robust oversight.

Positive Signals

Awarded under full and open competition, suggesting competitive pricing.
Firm fixed-price contract provides cost certainty for the government.
Contract duration of over 800 days allows for substantial development and ramp-up.
Contractor has a significant contract value, indicating capacity to handle large-scale projects.

Sector Analysis

This contract falls within the Research and Development in the Physical, Engineering, and Life Sciences sector, specifically supporting the expansion of manufacturing capabilities for diagnostic tests. The market for COVID-19 testing and diagnostics has seen significant growth and investment since the pandemic began. Comparable spending benchmarks would likely be found in other large-scale manufacturing or supply chain enhancement contracts within the life sciences or public health sectors.

Small Business Impact

The data indicates that this contract was not set aside for small businesses (ss: false, sb: false). Therefore, there are no direct subcontracting implications for small businesses stemming from a set-aside provision. The primary impact on the small business ecosystem would be indirect, potentially through opportunities if Hamilton Company engages them as suppliers or partners in their expanded manufacturing operations.

Oversight & Accountability

Oversight for this contract would primarily reside with the Department of Health and Human Services (DHHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). Accountability measures are embedded in the firm fixed-price contract terms, requiring delivery of specified manufacturing capacity. Transparency is facilitated by the contract award notice, but detailed performance metrics and oversight reports would be necessary for a full assessment.

Related Government Programs

COVID-19 Testing and Diagnostics
Public Health Preparedness
Medical Manufacturing
Supply Chain Resilience

Risk Flags

Potential supply chain vulnerability if contractor faces disruptions.
Dependence on contractor's ability to scale production effectively.
Need for robust quality assurance to ensure diagnostic accuracy.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $115.1 million to HAMILTON COMPANY. HAMILTON COMPANY FOR MFG CAPACITY EXPANSION OF COVID-19 DHHS TESTING AND DIAGNOSTICS. THIS ACTION WAS IN SUPPORT OF DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS)

Who is the contractor on this award?

The obligated recipient is HAMILTON COMPANY.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $115.1 million.

What is the period of performance?

Start: 2022-02-17. End: 2024-04-30.

What is Hamilton Company's track record with large federal contracts, particularly in manufacturing or R&D for public health initiatives?

Hamilton Company has a history of engaging with federal agencies, including significant work related to scientific instrumentation and manufacturing. While specific details on past public health manufacturing expansion contracts are not provided in this data snippet, their established presence in related fields suggests a capacity for undertaking such projects. A deeper dive into their contract history with agencies like NIH, NSF, or DoD would reveal their performance on similar large-scale, technically complex endeavors. Their experience in precision manufacturing and automation is likely a key factor in their selection for this DHHS contract, indicating a baseline capability to execute the required expansion.

How does the $115.1 million contract value compare to typical investments in expanding diagnostic manufacturing capacity?

The $115.1 million contract value is substantial and reflects the significant investment required to scale up manufacturing capacity for critical medical supplies like COVID-19 tests. Typical investments can vary widely based on the complexity of the technology, the scale of expansion, and the specific type of diagnostic. For instance, establishing new, highly automated production lines for molecular diagnostics could easily run into tens or hundreds of millions of dollars. This figure appears to be in line with large-scale government initiatives aimed at bolstering domestic manufacturing capabilities for essential health products, especially during a public health emergency. Without knowing the exact scope (e.g., number of new lines, automation level, specific tests), a precise comparison is challenging, but the amount suggests a significant expansion effort.

What are the primary risks associated with this contract, and how are they being mitigated?

Key risks include potential delays in manufacturing ramp-up, quality control issues during expansion, and supply chain disruptions for raw materials. The firm fixed-price contract structure mitigates financial risk for the government by capping costs, but it places the execution risk on Hamilton Company. Mitigation strategies likely involve robust project management by Hamilton, clear performance milestones, and ongoing oversight from DHHS. The contract duration of over 800 days allows for a phased approach, potentially mitigating risks associated with rapid scaling. Furthermore, the government's reliance on a single contractor for this specific expansion could be a risk if alternative suppliers are not readily available.

What is the expected impact of this contract on the availability and cost of COVID-19 testing?

The primary expected impact is a significant increase in the domestic manufacturing capacity for COVID-19 testing and diagnostics. This enhanced capacity should lead to greater availability of tests, reducing potential shortages and improving response times during surges in demand. By potentially lowering per-unit production costs through economies of scale and optimized manufacturing processes, the contract could also contribute to stabilizing or even reducing the cost of testing over the long term. The success of this expansion will directly influence the government's ability to maintain adequate testing supplies.

How does this contract fit into the broader federal strategy for pandemic preparedness and response?

This contract is a direct investment in strengthening the nation's pandemic preparedness infrastructure by bolstering domestic manufacturing capabilities for essential diagnostic tools. It aligns with a broader strategy to reduce reliance on foreign supply chains and ensure a rapid, scalable response to future public health emergencies. By expanding capacity now, the government aims to avoid the critical shortages experienced early in the COVID-19 pandemic. This proactive measure supports the goal of maintaining a robust and responsive healthcare system capable of meeting unforeseen demands.

What is the significance of the 'Research and Development in the Physical, Engineering, and Life Sciences' NAICS code for this contract?

The NAICS code 541715, 'Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology),' indicates that the contract's primary purpose is related to advancing scientific knowledge and capabilities within these fields. For this specific contract, it signifies that the expansion of manufacturing capacity involves R&D elements, potentially in process optimization, new manufacturing techniques, or adapting existing technologies for large-scale diagnostic production. While the end goal is manufacturing, the underlying activities likely involve innovation and development to achieve efficient, high-volume output, justifying its classification under R&D.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: FA820321R0009

Offers Received: 64

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Hamilton Bonaduz AG

Address: 4970 ENERGY WY, RENO, NV, 89502

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $115,102,920

Exercised Options: $115,102,920

Current Obligation: $115,102,920

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Timeline